ToxiPep: Peptide toxicity prediction via fusion of context-aware representation and atomic-level graph
- PMID: 40529180
- PMCID: PMC12171765
- DOI: 10.1016/j.csbj.2025.05.039
ToxiPep: Peptide toxicity prediction via fusion of context-aware representation and atomic-level graph
Abstract
Peptide-based therapeutics have emerged as a promising avenue in drug development, offering high biocompatibility, specificity, and efficacy. However, the potential toxicity of peptides remains a significant challenge, necessitating the development of robust toxicity prediction methods. In this study, we introduce ToxiPep, a novel dual-model framework for peptide toxicity prediction that integrates sequence-based contextual information with atomic-level structural features. This framework combines BiGRU and Transformer to capture local and global sequence dependencies while leveraging multi-scale CNNs to extract refined structural features from molecular graphs derived from peptide SMILES representations. A cross-attention mechanism aligns and fuses these two feature modalities, enabling the model to capture intricate relationships between sequence and structural information. ToxiPep outperforms several state-of-the-art tools, including ToxinPred2, CSM-Toxin, PepNet, and ToxinPred3, on both internal and independent test sets. Additionally, interpretability analyses reveal that ToxiPep identifies key amino acids along with their structural features, providing insights into the molecular mechanisms of peptide toxicity. To facilitate broader accessibility, we have also developed a web server for convenient user access. Overall, this framework has the potential to accelerate the identification of safer therapeutic peptides, offering new opportunities for peptide-based drug development in precision medicine.
Keywords: Deep learning; Drug discovery; Peptide bioactivity prediction; Sequence modeling.
© 2025 Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.
Conflict of interest statement
The authors have declared no conflict of interest.
Figures
References
-
- Craik David J., Fairlie David P., Liras Spiros, Price David. The future of peptide-based drugs. Chem Biol Drug Des. 2013;81(1):136–147. - PubMed
-
- Rastogi Shruti, Shukla Shatrunajay, Kalaivani M., Singh Gyanendra Nath. Peptide-based therapeutics: quality specifications, regulatory considerations, and prospects. Drug Discov Today. 2019;24(1):148–162. - PubMed
-
- Haggag Yusuf A., Donia Ahmed A., Osman Mohamed A., El-Gizawy Sanaa A. Peptides as drug candidates: limitations and recent development perspectives. Biomed J. 2018;1(3)
LinkOut - more resources
Full Text Sources